Cure8 research brief
Vulvar Crohn’s is a rare, often treatment-refractory manifestation. Reports that ustekinumab and risankizumab helped patients may expand options for people with cutaneous Crohn’s disease, especially after anti–TNF failure.
Adult patients with Crohn’s disease who have cutaneous or vulvar involvement; clinicians managing IBD, dermatology, and gynecology; specialists considering biologic switches after anti–TNF failure.
This article presents three cases of vulvar Crohn’s disease managed with biologic therapy. Ustekinumab is reported to have achieved symptom remission in one case, and risankizumab helped control disease in another. The authors emphasize tailoring biologic choice based on disease location, extent, prior treatments, and infection/immunosuppression risks.
Decisions about biologic therapy for vulvar Crohn’s require individualized assessment and specialist involvement (dermatology, gynecology, and IBD teams). The report adds to growing clinical experience supporting IL-targeted therapies for refractory cutaneous Crohn’s manifestations, particularly after anti–TNF failure.
This is an abstract-level case series (three patients) reported in a specialty journal; it describes clinical experience rather than results from randomized trials. Use the information as contextual clinical evidence, not definitive guidance.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
